Skip to main content
logo
Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
19.31
-1.86 (-8.79%)
At close: Oct 6, 2026, 4:00 PM EDT
19.18
-0.13 (-0.67%)
Pre-market: Oct 7, 2026, 8:02 AM EDT

Immunome Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-6.949.0414.02--
Revenue Growth
--23.23%-35.50%---
Gross Profit
-206.23-170.35-120.5-9.07-23.11-
Operating Income
-260.47-214.11-153.46-28.73-36.9-25.2
Net Income
-254.32-212.39-292.96-106.81-37.52-24.71
Earnings Per Share
-2.49-2.43-5.00-5.38-3.09-2.14
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
520653.48217.3138.1420.3249.23
Total Debt
4.743.864.831.650.29-
Net Cash (Debt)
515.26649.63212.47136.4920.0349.23
Net Cash Growth
95.25%205.75%55.67%581.37%-59.31%25.74%
Net Cash Per Share
5.037.443.626.881.654.27

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-208.79-190.92-110.79-7.57-28.69-18.23
Capital Expenditures
-10.29-9.69-7.17-0.83-0.25-0.08
Free Cash Flow
-219.09-200.6-117.97-8.4-28.94-18.31
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----64.71%--
Operating Margin
--3084.76%-1697.33%-204.94%--
Pretax Margin
--3059.99%-3240.38%-761.92%--
Profit Margin
--3059.99%-3240.38%-761.92%--
FCF Margin
--2890.13%-1304.80%-59.92%--

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
-341.4473.3232.62--